# Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

> **NCT04438824** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Well-differentiated/Dedifferentiated Liposarcoma

## Interventions

- **DRUG:** INCMGA00012
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT04438824
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-17
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438824, "Palbociclib and INCMGA00012 in People With Advanced Liposarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04438824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*